Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors Journal Article

  

Authors:	Ku, G. Y.; O'Reilly, E. M.; Saltz, L. B.; Schrag, D.; Maki, R. G.; Kelsen, D. P.; Ilson, D. H.
Article Title:	Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors
Abstract:	We performed a phase I study of 5-fluorouracil (5-FU), cisplatin and irinotecan. Methods: Twenty-nine patients received cisplatin 25 mg/m<sup>2</sup> and bolus 5-FU 425 mg/m<sup>2</sup>, along with irinotecan at 40, 50, and 65 mg/m<sup>2</sup> weekly for 4 out of 6 weeks. Results: The maximum tolerated dose (MTD) for untreated patients was irinotecan 65 mg/m<sup>2</sup> while the MTD for previously treated patients was irinotecan 40 mg/m<sup>2</sup>. Neutropenia and diarrhea were the major dose-limiting toxicities. Antitumor activity was noted in gastric, esophageal and pancreatic cancers. Conclusion: Because of the toxicity profile, combinations with continuous infusion 5-FU or capecitabine should be explored. ©Informa Healthcare USA.
Keywords:	adult; clinical article; treatment outcome; aged; middle aged; clinical trial; constipation; disease course; fatigue; neutropenia; cisplatin; fluorouracil; advanced cancer; cancer combination chemotherapy; diarrhea; drug dose reduction; side effect; solid tumor; treatment duration; capecitabine; pancreas cancer; pancreatic neoplasms; drug megadose; antineoplastic agent; low drug dose; multiple cycle treatment; erythropoietin; anemia; leukopenia; nausea; neuropathy; antineoplastic combined chemotherapy protocols; drug administration schedule; camptothecin; dexamethasone; antineoplastic activity; continuous infusion; pathology; time; time factors; irinotecan; abdominal pain; drug dose escalation; febrile neutropenia; fever; prothrombin time; disease progression; chemically induced disorder; thrombosis; pancreas tumor; drug derivative; granisetron; stomach cancer; loperamide; maximum tolerated dose; phase 1 clinical trial; drug administration; recombinant granulocyte colony stimulating factor; esophagus cancer; 5-fluorouracil; infusions, intravenous; stomach neoplasms; esophagus tumor; esophageal neoplasms; phase i trial; atropine; digestive system tumor; intravenous drug administration; stomach tumor; digestive system neoplasms; injections, intravenous
Journal Title:	Cancer Investigation
Volume:	27
Issue:	4
ISSN:	0735-7907
Publisher:	Informa Healthcare
Date Published:	2009-04-01
Start Page:	402
End Page:	406
Language:	English
DOI:	10.1080/07357900802406327
PUBMED:	19219674
PROVIDER:	scopus
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-65249086351&partnerID=40&md5=652a08f2bdfe5a14485875bddaa480a1
Notes:	--- - "Export Date: 30 November 2010" - "CODEN: CINVD" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/860